finmarketnews.com
news-details
Healthcare & Biotech,Insiders

ADVM Showing Recent Insider Activity

Recent activity shows that Adverum Biotechnologies, ADVM the Insider Confidence level is trending Up due to Corporate Insiders of ADVM Bought $119.9K worth of shares in the last 3 months.  

Before you dig into this report it is important to remember that "Insider Buying" is the purchase of shares in a corporation by a director, officer, or executive within the company. Insider buying is not the same as insider trading, which refers to corporate insiders making illegal stock purchases based on non-public information.
 
"Insider Buying" is not a crime when the buying is based on public information. 
 
Additionally, since insiders have unique insights into their own companies, they often gobble up shares when they believe the stock is undervalued or dump stock when it’s time to sell.  That's why people pay attention to insider buying.

Here is a list of the latest insider activity for ADVM:
  • Beckman Richard - CMO, Bought $8,200 worth of shares on 1 week ago
  • Seyedkazemi Setareh - CDO, Bought $16,800 worth of shares on 2 days ago
  • Dawn Graham - Director, Bought $25,500 worth of shares on 1 week ago
  • D'Souza Rupert - CFO, Bought $16,700 worth of shares on 1 week ago
TipRanks.com reports that Adverum Biotechnologies currently has 2 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $6.00 . The target pricing ranges from a high forecast of $6.00 down to a low forecast of $6.00. Adverum Biotechnologies (ADVM)’s last closing price was $0.885 which would put the average price target at 578.04% upside.

In addition, TradingView issued a Sell rating for ADVM over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook

Adverum Biotechnologies, ADVM
Summary: Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
  • Last Price: $0.885
  • Price Change: $0.0276, 3.2194%
  • Yearly Gain: -75.73%
  • Market Cap: $87.40M
  • P/E Ratio: -0.543
Remember, securities are volatile, so please do your own research on ADVM. If you are interest in stocks like ADVM or stocks in the Healthcare sector, please click here.

TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

When an ADVM analyst reiterates coverage on stocks, we will let you know.  Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.

This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to ADVM, you should consider joining TipRanks.com.

Disclaimer:
 Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data.
Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================